Trovagene Inc. (TROV) Rating Reiterated by Cantor Fitzgerald
Trovagene Inc. (NASDAQ:TROV)‘s stock had its “buy” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued on Thursday. They presently have a $8.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 162.30% from the company’s previous close.
Several other research analysts have also commented on the company. Maxim Group restated a “buy” rating and set a $9.00 price target on shares of Trovagene in a research report on Thursday, October 6th. Zacks Investment Research upgraded Trovagene from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a report on Wednesday, September 21st. Finally, Piper Jaffray Cos. set a $4.00 target price on Trovagene and gave the company a “hold” rating in a report on Friday, August 5th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Trovagene currently has an average rating of “Hold” and an average price target of $6.45.
Shares of Trovagene (NASDAQ:TROV) opened at 3.05 on Thursday. The stock’s market cap is $93.38 million. The firm’s 50-day moving average price is $4.07 and its 200 day moving average price is $4.65. Trovagene has a 1-year low of $2.85 and a 1-year high of $7.18.
Hedge funds have recently made changes to their positions in the company. Bridger Management LLC acquired a new stake in shares of Trovagene during the first quarter worth about $15,301,000. Vanguard Group Inc. increased its stake in shares of Trovagene by 3.2% in the second quarter. Vanguard Group Inc. now owns 979,014 shares of the company’s stock worth $4,435,000 after buying an additional 30,369 shares during the period. Northern Trust Corp increased its stake in shares of Trovagene by 1.0% in the third quarter. Northern Trust Corp now owns 312,732 shares of the company’s stock worth $1,404,000 after buying an additional 2,978 shares during the period. Advisor Group Inc. acquired a new stake in shares of Trovagene during the second quarter worth about $520,000. Finally, BlackRock Investment Management LLC increased its stake in shares of Trovagene by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 113,232 shares of the company’s stock worth $513,000 after buying an additional 5,964 shares during the period. 31.05% of the stock is owned by institutional investors.
Trovagene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Stock Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related stocks with our FREE daily email newsletter.